These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25482410)

  • 1. Mutation analysis of large tumor suppressor genes LATS1 and LATS2 supports a tumor suppressor role in human cancer.
    Yu T; Bachman J; Lai ZC
    Protein Cell; 2015 Jan; 6(1):6-11. PubMed ID: 25482410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
    Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
    J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer.
    Yu T; Bachman J; Lai ZC
    Genetics; 2013 Nov; 195(3):1193-6. PubMed ID: 24026096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y; Chun A; Cheung K; Rashidi B; Yang X
    J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
    Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
    Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of the interaction of the breast cancer oncogene LMO4 with the tumour suppressor CtIP/RBBP8.
    Stokes PH; Liew CW; Kwan AH; Foo P; Barker HE; Djamirze A; O'Reilly V; Visvader JE; Mackay JP; Matthews JM
    J Mol Biol; 2013 Apr; 425(7):1101-10. PubMed ID: 23353824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
    Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
    J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lats2 is critical for the pluripotency and proper differentiation of stem cells.
    Aylon Y; Sarver A; Tovy A; Ainbinder E; Oren M
    Cell Death Differ; 2014 Apr; 21(4):624-33. PubMed ID: 24413153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LATS tumor suppressor: a new governor of cellular homeostasis.
    Visser S; Yang X
    Cell Cycle; 2010 Oct; 9(19):3892-903. PubMed ID: 20935475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.
    Mei L; Yuan L; Shi W; Fan S; Tang C; Fan X; Yang W; Qian Y; Hussain M; Wu X
    Cancer Lett; 2017 Feb; 386():1-11. PubMed ID: 27847303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
    Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
    Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.
    Powzaniuk M; McElwee-Witmer S; Vogel RL; Hayami T; Rutledge SJ; Chen F; Harada S; Schmidt A; Rodan GA; Freedman LP; Bai C
    Mol Endocrinol; 2004 Aug; 18(8):2011-23. PubMed ID: 15131260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis.
    Yabuta N; Mukai S; Okada N; Aylon Y; Nojima H
    Cell Cycle; 2011 Aug; 10(16):2724-36. PubMed ID: 21822051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo pathway member Nf2 is required for inner cell mass specification.
    Cockburn K; Biechele S; Garner J; Rossant J
    Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.
    Furth N; Aylon Y
    Cell Death Differ; 2017 Sep; 24(9):1488-1501. PubMed ID: 28644436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
    Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
    Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unlikely player joins the ATM signalling network.
    Lavin MF
    Nat Cell Biol; 2000 Dec; 2(12):E215-7. PubMed ID: 11146665
    [No Abstract]   [Full Text] [Related]  

  • 19. N-terminal truncation of Lats1 causes abnormal cell growth control and chromosomal instability.
    Yabuta N; Mukai S; Okamoto A; Okuzaki D; Suzuki H; Torigata K; Yoshida K; Okada N; Miura D; Ito A; Ikawa M; Okabe M; Nojima H
    J Cell Sci; 2013 Jan; 126(Pt 2):508-20. PubMed ID: 23230145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane.
    Hergovich A; Schmitz D; Hemmings BA
    Biochem Biophys Res Commun; 2006 Jun; 345(1):50-8. PubMed ID: 16674920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.